Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.

Abstract:

BACKGROUND AND OBJECTIVE:Olanzapine is an atypical antipsychotic indicated for the treatment of schizophrenia and, either as monotherapy or as an adjunct to lithium or valproate, for bipolar I disorder. Multiple daily doses of olanzapine do not affect the pharmacokinetics of lithium or valproate; therefore, concomitant olanzapine administration does not require dosage adjustment of lithium or valproate. ALKS 3831, a combination of olanzapine and the opioid receptor antagonist samidorphan (OLZ/SAM), is currently under development to provide the established antipsychotic efficacy of olanzapine while mitigating olanzapine-induced weight gain. Olanzapine is recognized as one of the most efficacious antipsychotics; however, the benefits of olanzapine are offset by its propensity to cause significant weight gain, which may lead to long-term metabolic sequelae. This study evaluated the effects of multiple daily doses of OLZ/SAM on the pharmacokinetics of lithium or valproate in healthy subjects. METHODS:This was an open-label, single-sequence, two-cohort study (ALKS3831-B101) conducted at a single center in the USA. Thirty-four healthy adult subjects were assigned (1:1) to receive lithium carbonate 300-mg tablets (cohort 1) or divalproex sodium 500-mg tablets (cohort 2), once every 12 h on days 1-7. Once-daily oral doses of OLZ/SAM (olanzapine 10 mg/samidorphan 10 mg) bilayer tablets were administered on days 8-18. Subjects resumed every 12-h doses of lithium or valproate concomitantly with the once-daily oral doses of OLZ/SAM on days 12-18. Plasma concentrations of lithium and valproic acid (valproate) were quantified in blood samples collected prior to and up to 12 h after lithium or valproate dose administration on days 7 and 18. Pharmacokinetic parameters of lithium and valproate, including maximum plasma concentration and area under the plasma concentration-time curve over a 12-h dosing interval, were calculated. The ratio of geometric means of maximum plasma concentration and area under the plasma concentration-time curve over a 12-h dosing interval in the presence and absence of OLZ/SAM, and its two-sided 90% confidence intervals, were derived from a mixed-effects model. Adverse events were monitored throughout the study. RESULTS:The 90% confidence intervals for the ratios of geometric means, in the presence vs. absence of OLZ/SAM, were within the equivalence interval of 80-125% for both maximum plasma concentration and area under the plasma concentration-time curve over a 12-h dosing interval of lithium and of valproate. The safety profiles of lithium or valproate co-administered with OLZ/SAM were consistent with what has been previously reported for lithium or valproate. The safety profile of OLZ/SAM was consistent with that observed in previous clinical studies with OLZ/SAM. CONCLUSIONS:Consistent with previously reported findings on olanzapine, administration of multiple doses of OLZ/SAM did not have a clinically significant effect on the pharmacokinetics of lithium or valproate. Co-administration of OLZ/SAM and lithium or valproate was generally well tolerated; the safety profile of OLZ/SAM was consistent with that observed in previous clinical studies.

journal_name

Clin Drug Investig

authors

Sun L,Yagoda S,Yao B,Graham C,von Moltke L

doi

10.1007/s40261-019-00860-y

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

55-64

issue

1

eissn

1173-2563

issn

1179-1918

pii

10.1007/s40261-019-00860-y

journal_volume

40

pub_type

杂志文章
  • Reduction in opioid-related adverse events and improvement in function with parecoxib followed by valdecoxib treatment after non-cardiac surgery: a randomized, double-blind, placebo-controlled, parallel-group trial.

    abstract:BACKGROUND:Multimodal pain therapy including cyclo-oxygenase-2 inhibitors can result in optimal pain management with decreased opioid use and fewer opioid-related adverse events. Patient reported outcomes (PROs) help identify benefits in reduced opioid use and increased pain control. METHODS:In this randomized, double...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/11317570-000000000-00000

    authors: Langford RM,Joshi GP,Gan TJ,Mattera MS,Chen WH,Revicki DA,Chen C,Zlateva G

    更新日期:2009-01-01 00:00:00

  • Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.

    abstract::The aim of this case study was to examine the efficacy of a dipeptidyl peptidase-4 inhibitor (anagliptin) and an α-glucosidase inhibitor (miglitol) when added to ongoing insulin treatment in patients with type 2 diabetes mellitus. Continuous glucose monitoring was performed in four Japanese insulin-treated inpatients ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0260-8

    authors: Kishimoto M,Noda M

    更新日期:2015-02-01 00:00:00

  • Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study.

    abstract:BACKGROUND:Congestion is the main cause of morbidity in patients with heart failure. Treatment of fluid overload is often challenging in everyday clinical practice. OBJECTIVE:The aim of this study was to determine the diuretic effect of acetazolamide in patients with exacerbations of chronic heart failure, in addition...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-017-0577-1

    authors: Imiela T,Budaj A

    更新日期:2017-12-01 00:00:00

  • Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

    abstract::This narrative review summarises the benefits, risks and appropriate use of acid-suppressing drugs (ASDs), proton pump inhibitors and histamine-2 receptor antagonists, advocating a rationale balanced and individualised approach aimed to minimise any serious adverse consequences. It focuses on current controversies on ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-017-0519-y

    authors: Fisher L,Fisher A

    更新日期:2017-07-01 00:00:00

  • Opioid Use and Pain Control in the Elderly After Elective or Urgent Orthopaedic Surgery: A Retrospective Cohort Study.

    abstract:BACKGROUND:As an increasing number of elderly are undergoing orthopaedic procedures, it is important to understand and evaluate postoperative pain management in this population, especially in regard to opioid use. Data in the literature pertaining to the very elderly remains scarce. OBJECTIVES:This study was conducted...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-00744-7

    authors: Dagenais-Beaulé V,Tourigny JF,Papillon-Ferland L

    更新日期:2019-03-01 00:00:00

  • Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases.

    abstract::A pharmacokinetic study was carried out in patients with unresectable colorectal liver metastases who had primarily been included in a phase II trial of intra-arterial cisplatin (DDP) plus intravenous fluorouracil. Ten patients of those accrued for the clinical study underwent the pharmacokinetic investigation upon li...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199612020-00005

    authors: Civalleri D,Esposito M,De Cain F,Balletto N,Mondini G,Gogioso L,Viale M,Vannozzi MO

    更新日期:1996-08-01 00:00:00

  • Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.

    abstract::We report the long-term effects of deferasirox 10-30 mg/kg/day on cardiac iron overload in a case series of five patients with transfusion-dependent beta-thalassaemia major who underwent up to 5 years of chelation therapy. Iron overload was monitored by multislice multi-echo T2* magnetic resonance imaging (MRI). Overa...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11534480-000000000-00000

    authors: Ruffo GB,Borsellino Z,Cuccia L,Marocco MR,Gagliardotto F,Tarantino R

    更新日期:2010-01-01 00:00:00

  • Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.

    abstract:BACKGROUND AND OBJECTIVES:Dasotraline is a novel inhibitor of dopamine and norepinephrine reuptake currently being investigated in clinical studies for the treatment of attention-deficit/hyperactivity disorder (ADHD). Uniquely, relative to current ADHD medications, dasotraline has a slow absorption and long elimination...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0358-7

    authors: Hopkins SC,Sunkaraneni S,Skende E,Hing J,Passarell JA,Loebel A,Koblan KS

    更新日期:2016-02-01 00:00:00

  • Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.

    abstract:BACKGROUND AND OBJECTIVE:Interferon-alpha treatment is associated with a large number of adverse effects. Depressive symptoms are not unexpected, and potentially dangerous psychiatric adverse effects can induce life-threatening conditions. We compared the incidence of depressive symptoms in patients with chronic hepati...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00044011-200626110-00005

    authors: Neri S,Pulvirenti D,Bertino G

    更新日期:2006-01-01 00:00:00

  • Oral Teicoplanin as an Alternative First-Line Regimen in Clostridium difficile Infection in Elderly Patients: A Case Series.

    abstract:BACKGROUND:Elderly patients are more susceptible to Clostridium difficile infections (CDIs). Despite existing guidelines, there is no specific treatment for CDI in geriatrics. Vancomycin is commonly used in the treatment of CDI. Teicoplanin is an alternative glycopeptide which recently received marketing authorization ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0524-1

    authors: Davido B,Leplay C,Bouchand F,Dinh A,Villart M,Le Quintrec JL,Teillet L,Salomon J,Michelon H

    更新日期:2017-07-01 00:00:00

  • Safety of lornoxicam in the treatment of postoperative pain: a post-marketing study of analgesic regimens containing lornoxicam compared with standard analgesic treatment in 3752 day-case surgery patients.

    abstract:BACKGROUND:Post-marketing surveillance studies can provide supplemental data on the safety of medications in the general population. OBJECTIVE:This study aimed to evaluate the safety of analgesic regimens including the NSAID lornoxicam in the short-term treatment of postoperative pain in a clinically relevant populati...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/11538860-000000000-00000

    authors: Rawal N,Krøner K,Simin-Geertsen M,Hejl C,Likar R

    更新日期:2010-01-01 00:00:00

  • Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.

    abstract:BACKGROUND AND OBJECTIVE:Injectable collagenase Clostridium histolyticum is efficacious in correcting Dupuytren's contracture as assessed by changes in the angle of contracture and range of motion (ROM). However, clinically important changes in ROM have not been evaluated in depth. The objective of this secondary analy...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/BF03256918

    authors: Witthaut J,Bushmakin AG,Gerber RA,Cappelleri JC,Le Graverand-Gastineau MP

    更新日期:2011-11-01 00:00:00

  • Efficacy and tolerability of a fixed-dose combination of metoprolol extended release/amlodipine in patients with mild-to-moderate hypertension: a randomized, parallel-group, multicentre comparison with losartan plus amlodipine.

    abstract:BACKGROUND:Epidemiological studies and clinical trials have shown that prevention of cardiovascular disease, the ultimate goal of hypertension treatment, requires a sufficient reduction in blood pressure. OBJECTIVE:The primary objective of this study was to compare the mean decrease in systolic (SBP) and diastolic (DB...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/11531770-000000000-00000

    authors: Pareek A,Chandurkar NB,Sharma R,Tiwari D,Gupta BS

    更新日期:2010-01-01 00:00:00

  • Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database.

    abstract:BACKGROUND AND OBJECTIVES:Schizophrenia is a severe public health problem and one of the top ten causes of disability, affecting about 1.1% of the world's population. Paliperidone is a new atypical antipsychotic used to treat schizophrenia. Several case reports about unexpected adverse drug reactions of paliperidone ha...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00945-z

    authors: Seo DE,Kim S,Park BJ

    更新日期:2020-09-01 00:00:00

  • Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.

    abstract:OBJECTIVE:Weight gain during insulin therapy can be a challenging problem in already overweight type 2 diabetes mellitus patients, affecting treatment compliance and long-term prognosis. The analogue insulin detemir has been reported to have a weight-sparing effect compared with other basal insulins. This pooled analys...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200727040-00007

    authors: Raslová K,Tamer SC,Clauson P,Karl D

    更新日期:2007-01-01 00:00:00

  • Safety and tolerability of high-dose budesonide/formoterol via Turbuhaler® in Japanese patients with asthma: a randomized, double-blind, crossover, active comparator-controlled, phase III study.

    abstract:BACKGROUND:The use of budesonide/formoterol as both maintenance and reliever therapy in asthma is recommended in many countries; however, there are limited data available for the Asian patient population. OBJECTIVE:This study aimed to evaluate the short-term safety and tolerability of a fixed high-dose combination of ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11595440-000000000-00000

    authors: Saito T,Hasunuma T

    更新日期:2012-01-01 00:00:00

  • Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review.

    abstract:BACKGROUND:Warfarin is a commonly used oral anticoagulant and its interaction with other drugs can result in serious thrombotic or bleeding events. Currently, there is no definitive evidence on the possibility of an interaction between warfarin and oseltamivir. OBJECTIVE:The objective of this study was to investigate ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11595860-000000000-00000

    authors: Lee SH,Kang HR,Jung JW,Kwon JW,Hong KS,Yu KS,Cho SH

    更新日期:2012-02-01 00:00:00

  • Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation.

    abstract:BACKGROUND:European guidelines do not recommend the use of carbamazepine, levetiracetam, phenobarbital, phenytoin, topiramate and valproic acid in patients taking direct oral anticoagulants (DOACs). Little is known regarding the clinical relevance of the interaction between DOACs and antiepileptic drugs. OBJECTIVES:To...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00982-8

    authors: Giustozzi M,Mazzetti M,Paciaroni M,Agnelli G,Becattini C,Vedovati MC

    更新日期:2021-01-01 00:00:00

  • The effect of active vitamin D administration on muscle mass in hemodialysis patients.

    abstract:BACKGROUND:Muscle wasting is common and insidious in end-stage renal disease (ESRD). Loss of muscle quantity and quality reduces quality of life and increases mortality in ESRD patients. Additionally, secondary hyperparathyroidism (SHPT) causes muscle atrophy. Meanwhile, vitamin D, which is used for SHPT treatment, pla...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-013-0132-7

    authors: Mori A,Nishino T,Obata Y,Nakazawa M,Hirose M,Yamashita H,Uramatsu T,Shinzato K,Kohno S

    更新日期:2013-11-01 00:00:00

  • Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.

    abstract:BACKGROUND AND OBJECTIVE:Icosapent ethyl is a high-purity prescription form of eicosapentaenoic acid ethyl ester approved as an adjunct to diet to reduce triglyceride levels in adult patients with triglyceride levels ≥500 mg/dL (≥5.65 mmol/L). The objective of this open-label, drug-drug interaction study was to examine...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0252-8

    authors: Braeckman RA,Stirtan WG,Soni PN

    更新日期:2015-01-01 00:00:00

  • Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers.

    abstract:OBJECTIVE:Central nervous effects of oral anticholinergics may limit the success of incontinence therapy and patient compliance. Only a few studies investigating this topic are available. This study was conducted to determine whether oral anticholinergics alter sleep and psychometric test parameters. DESIGN:Randomised...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200323060-00003

    authors: Diefenbach K,Donath F,Maurer A,Quispe Bravo S,Wernecke KD,Schwantes U,Haselmann J,Roots I

    更新日期:2003-01-01 00:00:00

  • Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.

    abstract::Appropriate and successful management of pain with opioid analgesics is based on tailoring pharmacologic treatment to the individual and identifying the minimal effective dose at which pain is controlled with minimal adverse effects. Morphine and morphine-like-agonists exhibit similar pharmacodynamic profiles, but sub...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/0044011-200929001-00002

    authors: Geppetti P,Benemei S

    更新日期:2009-01-01 00:00:00

  • Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review.

    abstract::Androgenetic alopecia (AGA) is characterized by non-scarring follicle miniaturization. Despite the success of approved therapies, commonly reported side effects and the need for continual use has led to the investigation of alternative therapies. The aim of this paper is to critically review the success of off-label, ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-018-00743-8

    authors: Gupta AK,Mays RR,Versteeg SG,Shear NH,Piguet V,Piraccini BM

    更新日期:2019-03-01 00:00:00

  • Relative Bioavailability of Two Enteric-Coated Formulations of Omeprazole following Repeated Doses in Healthy Volunteers.

    abstract:OBJECTIVE:This study aimed to investigate the relative bioavailability and bioequivalence of two omeprazole enteric-coated formulations following repeated doses (steady state) in healthy male and female adult volunteers. DESIGN AND STUDY PARTICIPANTS:The study formulation (Ompranyt® 20mg capsules, Bial-Industrial Farm...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200121030-00006

    authors: Vaz-da-Silva M,Hainzl D,Almeida L,Dolgner A,Silveira P,Maia J,Soares-da-Silva P

    更新日期:2001-03-01 00:00:00

  • Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.

    abstract:BACKGROUND:Aliskiren is the first oral direct renin inhibitor to be approved for the treatment of hypertension. The pharmacokinetic and pharmacodynamic profile of aliskiren has been extensively characterized in Caucasian individuals; however, drug disposition, treatment response and tolerability can vary among ethnic g...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11533050-000000000-00000

    authors: Hu P,Bartlett M,Karan RS,Jiang J,Zhang S,Zhang J,Howard D,Yeh CM,Al-Fayoumi S,Jarugula V,Dole WP

    更新日期:2010-01-01 00:00:00

  • 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.

    abstract::Intramuscular 17 α-hydroxyprogesterone caproate (Makena(®)), a synthetic progestin, is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of a singleton spontaneous preterm birth. Makena(®) reduces the risk of preterm birth in this patient population, and is associated...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-013-0060-6

    authors: Hines M,Lyseng-Williamson KA,Deeks ED

    更新日期:2013-03-01 00:00:00

  • Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

    abstract::Page 806, column 1, line 3: The text, which previously read. ...

    journal_title:Clinical drug investigation

    pub_type: 已发布勘误

    doi:10.1007/s40261-020-00892-9

    authors: Lyseng-Williamson KA

    更新日期:2020-03-01 00:00:00

  • High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease.

    abstract:OBJECTIVE:To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD). DESIGN AND PATIENTS:Randomised, double-blind, double-dummy, placebo-controlled study in 123 patients experiencing an acute exacerba...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525060-00005

    authors: Zuin R,Palamidese A,Negrin R,Catozzo L,Scarda A,Balbinot M

    更新日期:2005-01-01 00:00:00

  • Oral Contraceptives and Neutropenia: A Population-Based Cohort Study.

    abstract:BACKGROUND:Oral contraceptives (OCs) are one of the most commonly used classes of drugs worldwide. A case of neutropenia and associated infections in a young woman using OCs that settled after discontinuation and reappeared upon re-challenge, has led us to investigate a potential association between oral contraceptives...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-019-00818-0

    authors: Rosenthal YS,Chodick G,Rosenthal A,Shalev V,Ram HS,Koren G

    更新日期:2019-10-01 00:00:00

  • Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study.

    abstract:BACKGROUND AND OBJECTIVES:Fentanyl buccal soluble film (FBSF) is a small, bilayered, water-soluble polymer film (BioErodible MucoAdhesive; BEMA™) that adheres to the buccal mucosa and rapidly delivers fentanyl into the systemic circulation. It is approved for the treatment of cancer breakthrough pain in adult opioid-to...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11594670-000000000-00000

    authors: Finn AL,Vasisht N,Stark JG,Gever LN,Tagarro I

    更新日期:2012-01-01 00:00:00